Defining the biologic role of genes that regulate prostate cancer metastasis

Current Opinion in Urology

Volumn 10, Issue 5, 2000, Pages 397-401

  Rinker Schaeffer, Carrie W ^a   Welch, Daniel R ^b   Sokoloff, Mitchell ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER GENETICS; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; DISEASE MODELS, ANIMAL; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RATS;

EID: 0033817917     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200009000-00006     Document Type: Article

References (63)

1. Cancer Statistics, 2000
2. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years
3. Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate
4. Nerve-sparing radical prostatectomy: Extraprostatic tumor extension and preservation of erectile function
5. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes
6. Development of markers of prostate cancer metastasis: Review and perspective
7. Early prostate-specific antigen relapse after radical retropubic prostatectomy: Prediction on the basis of preoperative and postoperative tumor characteristics
8. Rising PSA after local therapy failure: Immediate vs deferred treatment
9. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer
10. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy
11. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years
12. Hormone-refractory prostate cancer: An evolving standard of care
13. Natural course of localized prostate cancer: A personal view with a review of published papers
14. Therapeutic strategies for localized prostate cancer
15. Clinical Targets for anti-metastasis therapy
16. The pathogenesis of cancer metastasis
17. What defines a useful marker of metastasis in human cancer?
18. Molecular basis of tumour metastasis
19. Metastasis-suppressor genes: A review and perspective on an emerging field
20. Genetic regulation of human breast carcinoma metastasis
21. Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes memorial award lecture
22. Critical determinants of melanoma metastasis
23. Regulation of tumor cell growth at organ-specific metastases
24. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
25. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
26. The risk of dying of prostate cancer in patients with clinically localized disease
27. Radical prostatectomy. Patterns of local failure and survival in 67 patients
28. Prostate cancer metastasis-suppressor genes: A current perspective
29. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2
30. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene
31. BrMS1: A human breast cancer metastasis-suppressor gene encoded on chromosome 11q13.1-q13.2
32. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17
33. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases
34. Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate
35. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats
36. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers
37. The Dunning Model
38. Characterization of the Dunning R3327H prostatic adenocarcinoma: An appropriate animal model for prostatic cancer
39. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents
40. Detection of candidates for cancer cell motility inhibitory protein in the Dunning adenocarcinoma model
41. The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells
42. The role of motility proteins and metastasis-suppressor genes in prostate cancer progression
43. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins
44. Localization of prostate cancer metastasis-suppressor activity on human chromosome 17
45. Metastasis suppressor gene(s) for rat prostate cancer on the long arm of human chromosome 7
46. Mapping of metastasis suppressor gene(s) for rat prostate cancer on the short arm of human chromosome 8 by irradiated microcell-mediated chromosome transfer
47. Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10
48. Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11
49. Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8
50. Identification of a novel metastasis-suppressor region on human chromosome 12
51. Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells
52. Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11
53. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer
54. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss
55. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer
56. Signal transduction by the c-Jun N-terminal kinase
57. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development
58. Regulation and function of the JNK subgroup of MAP kinases
59. SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis
60. Defective liver formation and liver cell apoptosis in mice lacking the stress signaling kinase SEK1/MKK4
61. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms
62. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene
63. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor